News

PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...
PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...
More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...
A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.
PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.
The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.
Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.
Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).
PCI Pharma Services, which is backed by Partners Group, Thomas H. Lee Partners and Frazier Healthcare, has acquired Bellwyck Pharma Services. Iris Dorbian - 11 February 2020 ...
PCI Pharma Services, a Philadelphia contract drug manufacturer, is investing $50 million into a new manufacturing facility in Rockford that's expected to create about 250 jobs.